International consortium publishes comprehensive roadmap for the clinical implementation of ogm in hematological malignancy applications

San diego, jan. 03, 2024 (globe newswire) -- bionano laboratories, a laboratory services business of bionano genomics, inc. (nasdaq: bngo), today announced the publication of the first framework paper for the clinical adoption and implementation of the optical genome mapping (ogm) workflow for hematological malignancy applications, a process utilized by bionano laboratories in the development of its laboratory developed test (ldt), marketed as ogm-dx™ hemeone. the framework, which was co-authored by an international consortium of 18 researchers from institutions including university of toronto, university health network, columbia university irving medical center, augusta university, greenwood genetic center, the university of texas md anderson cancer center, hospital del mar barcelona, hospital del mar research institute (imim), radboud university medical center, university of oulu, university hospitals leuven, universitat autÒnoma de barcelona, and children's hospital los angeles, is intended to help laboratories with the uniform adoption and implementation of an ogm workflow.
BNGO Ratings Summary
BNGO Quant Ranking